4SC pulls plug on domatinostat; Pharming says leniolisib meets both endpoints
The management board of 4SC has discontinued its domatinostat program after the most recent clinical data has been released, the company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
